Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation
This study provides compelling evidence that curcumol can reverse sorafenib resistance in HCC by modulating multiple signaling pathways, including PI3K/AKT and JAK/STAT3 pathways. Our findings suggest that curcumol holds promise as a novel therapeutic agent for overcoming drug resistance in HCC, offering a new avenue for clinical intervention.
Authors
- Jiaqi Zhang (ORCID: https://orcid.org/0000-0002-3580-9227)
- Xinchen Tian (ORCID: https://orcid.org/0000-0002-7517-3462)
- Shulong Jiang (ORCID: https://orcid.org/0000-0001-8034-6762)
- Xiaohan Jin
- Lingli Hao
- Qingbin Liu (ORCID: https://orcid.org/0009-0005-0157-924X)
- Fen Liu
- Ni Zhang (ORCID: https://orcid.org/0009-0005-0130-2240)
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3389/fphar.2025.1514997
- Citations
- 3
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Natural Science Foundation of Shandong Province